Human cardiomyocyte interaction with electrospun fibrinogen/gelatin nanofibers for myocardial regeneration

Journal of Biomaterials Science, Polymer Edition

Volumn 24, Issue 14, 2013, Pages 1660-1675

  Balasubramanian, Preethi ^a   Prabhakaran, Molamma P ^a   Kai, Dan ^b   Ramakrishna, Seeram ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cross linking; electrospinning; infarction; mechanical properties; tissue engineering

Indexed keywords

BIOMECHANICS; CARDIOLOGY; CELL CULTURE; CELL ENGINEERING; CELL PROLIFERATION; CELLS; CROSSLINKING; ELECTROSPINNING; MECHANICAL PROPERTIES; PROTEINS; TENSILE STRENGTH; TISSUE; TISSUE ENGINEERING; TISSUE REGENERATION;

BIOMATERIAL SCAFFOLDS; CHEMICAL CHARACTERIZATION; COMPOSITE SUBSTRATE; INDUSTRIALIZED NATIONS; INFARCTION; MYOCARDIAL INFARCTION; MYOSIN HEAVY CHAIN; POLYMERIC SCAFFOLD;

SCAFFOLDS (BIOLOGY);

ALPHA ACTININ; CONNEXIN 43; FIBRINOGEN; GELATIN; GLUTARALDEHYDE; MYOSIN HEAVY CHAIN; NANOFIBER; TROPONIN I;

ARTICLE; CELL CULTURE; CELL INTERACTION; CELL PROLIFERATION; CELL STRUCTURE; CHEMICAL REACTION; CONTACT ANGLE; CROSS LINKING; ELECTROSPINNING; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MUSCLE REGENERATION; NANOFABRICATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PROPERTY; TENSILE STRENGTH; TISSUE ENGINEERING;

BIOCOMPATIBLE MATERIALS; CELL ADHESION; CELL PROLIFERATION; FIBRINOGEN; GELATIN; HEART; HUMANS; MECHANICAL PROCESSES; MYOCYTES, CARDIAC; NANOFIBERS; REGENERATION; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84883547353     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2013.789958     Document Type: Article

References (43)

1. Vacanti, JP, and, Langer, R. 1999. Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet., 354: SI32-SI34.
2. Chen, QZ, Harding, SE, Ali, NN, Lyon, AR, and, Boccaccini, AR. 2008. Biomaterials in cardiac tissue engineering: ten years of research survey. Mat. Sci. Eng. R-Rep., 59: 1-37.
3. Zimmermann, WH, and, Eschenhagen, T. 2003. Cardiac tissue engineering for replacement therapy. Heart Fail. Rev., 8: 259-269.
4. Wess TJ. Collagen fibril form and function. In: Parry DAD, Squire JM, editors. Fibrous proteins: coiled-coils, collagen and elastomers. San Diego (CA): Elsevier; 2005. p. 341-374.
5. Dang, CV, Bell, WR, and, Shuman, M. 1989. The normal and morbid biology of fibrinogen. Am. J. Med., 87: 567-576.
6. Mosesson, MW. 2005. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost., 3: 1894-1904.
7. Mosesson, MW, Siebenlist, KR, and, Meh, DA. 2001. " The structure and biological features of fibrinogen and fibrin ". In Fibrinogen, Edited by: Nieuwenhuizen, W, Mosesson, MW and DeMaat, MPM. 11-30. New York, NY: New York Academy of Sciences.
8. Shekhonin, BV, Guriev, SB, Irgashev, SB, and, Koteliansky, VE. 1990. Immunofluorescent identification of fibronectin and fibrinogen fibrin in experimental myocardial-infarction. J. Mol. Cell. Cardiol., 22: 533-541.
9. Willems, I, Arends, JW, and, Daemen, M. 1996. Tenascin and fibronectin expression in healing human myocardial scars. J. Pathol., 179: 321-325.
10. Caiado, F, Carvalho, T, Silva, F, Castro, C, Clode, N, Dye, JF, and, Dias, S. 2011. The role of fibrin E on the modulation of endothelial progenitors adhesion, differentiation and angiogenic growth factor production and the promotion of wound healing. Biomaterials., 32: 7096-7105.
11. Wiedemann, D, Schneeberger, S, Friedl, P, Zacharowski, K, Wick, N, Boesch, F, Margreiter, R, Laufer, G, Petzelbauer, P, and, Semsroth, S. 2010. The fibrin-derived peptide B beta(15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. Transplantation., 89: 824-829.
12. Barsotti, MC, Felice, F, Balbarini, A, and, Di Stefano, R. 2011. Fibrin as a scaffold for cardiac tissue engineering. Biotechnol. Appl. Biochem., 58: 301-310.
13. Ghasemi-Mobarakeh, L, Prabhakaran, MP, Morshed, M, Nasr-Esfahani, M, and, Ramakrishna, S. 2008. Electrospun poly (-caprolactone)/gelatin nanofibrous scaffolds for nerve tissue engineering. Biomaterials., 29: 4532-4539.
14. Li, M, Guo, Y, Wei, Y, MacDiarmid, AG, and, Lelkes, PI. 2006. Electrospinning polyaniline-contained gelatin nanofibers for tissue engineering applications. Biomaterials., 27: 2705-2715.
15. Huang, Y, Onyeri, S, Siewe, M, Moshfeghian, A, and, Madihally, SV. 2005. In vitro characterization of chitosan-gelatin scaffolds for tissue engineering. Biomaterials., 26: 7616-7627.
16. Kimura, Y, Ozeki, M, Inamoto, T, and, Tabata, Y. 2003. Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor. Biomaterials., 24: 2513-2521.
17. Balasubramanian, P, Prabhakaran, MP, Al Masri, AA, and, Ramakrishna, S. 2011. Injectable polymeric materials and evaluation of their in vivo functional assessment in cardiac tissue engineering. J. Biomater. Tissue Eng., 1: 149-165.
18. Olsen, D, Yang, CL, Bodo, M, Chang, R, Leigh, S, Baez, J, Carmichael, D, Perala, M, Hamalainen, ER, Jarvinen, M, and, Polarek, J. 2003. Recombinant collagen and gelatin for drug delivery. Adv. Drug Deliv. Rev., 55: 1547-1567.
19. Vandelli, MA, Rivasi, F, Guerra, P, Forni, F, and, Arletti, R. 2001. Gelatin microspheres crosslinked with d, l-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies. Int. J. Pharm., 215: 175-184.
20. Sakai, S, Hirose, K, Taguchi, K, Ogushi, Y, and, Kawakami, K. 2009. An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering. Biomaterials., 30: 3371-3377.
21. Wu, S-C, Chang, W-H, Dong, G-C, Chen, K-Y, Chen, Y-S, and, Yao, C-H. 2011. Cell adhesion and proliferation enhancement by gelatin nanofiber scaffolds. J. Bioact. Compat. Polym., 26: 565-577.
22. Davidson, MM, Nesti, C, Palenzuela, L, Walker, WF, Hernandez, E, Protas, L, Hirano, M, and, Isaac, ND. 2005. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol., 39: 133-147.
23. Xing, Y, Huang, P, and, Zhang, K. 2003. Cardiac troponin T and I: application in myocardial injury and forensic medicine. Fa yi xue za zhi., 19: 242-244.
24. Boengler, K, Heusch, G, and, Schulz, R. 2006. Connexin 43 and ischemic preconditioning: effects of age and disease. Exp. Gerontol., 41: 485-488.
25. Deten, A, Volz, HC, Briest, W, and, Zimmer, HG. 2002. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc. Res., 55: 329-340.
26. Christman, KL, and, Lee, RJ. 2006. Biomaterials for the treatment of myocardial infarction. J. Am. Coll. Cardiol., 48: 907-913.
27. Blomback, B, and, Blomback, M. 1972. Molecular-structure of fibrinogen. Ann. N.Y. Acad. Sci., 202: 77-97.
28. Sahni, A, and, Francis, CW. 2000. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood., 96: 3772-3778.
29. Rybarczyk, BJ, Lawrence, SO, and, Simpson-Haidaris, PJ. 2003. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. Blood., 102: 4035-4043.
30. Wilhelmsen, L, Svardsudd, K, Korsanbengtsen, K, Larsson, B, Welin, L, and, Tibblin, G. 1984. Fibrinogen as a risk factor for stroke and myocardial-infarction. N. Engl. J. Med., 311: 501-505.
31. Ma, J, Hennekens, CH, Ridker, PM, and, Stampfer, MJ. 1999. A prospective study of fibrinogen and risk of myocardial infarction in the physicians health study. J. Am. Coll. Cardiol., 33: 1347-1352.
32. Speiser, B, Riess, CF, and, Schaper, J. 1991. The extracellular-matrix in human myocardium.1. Collagens i, iii, iv, and vi. Cardioscience., 2: 225-232.
33. Carr, ME, and, Gabriel, DA. 1980. Dextran-induced changes in fibrin fiber size and density based on wavelength dependence of gel turbidity. Macromolecules., 13: 1473-1477.
34. Elsdale, T, and, Bard, J. 1972. Collagen substrata for studies on cell behavior. J. Cell Biol., 54: 626-637.
35. Khor, E. 1997. Methods for the treatment of collagenous tissues for bioprostheses. Biomaterials., 18: 95-105.
36. Jayakrishnan, A, and, Jameela, SR. 1996. Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices. Biomaterials., 17: 471-484.
37. Goissis, G, Junior, EM, Marcantonio, JAC, Lia, RCC, Cancian, DCJ, and, de Carvalho, M. 1999. Biocompatibility studies of anionic collagen membranes with different degree of glutaraldehyde cross-linking. Biomaterials., 20: 27-34.
38. Zhang, YZ, Venugopal, J, Huang, ZM, Lim, CT, and, Ramakrishna, S. 2006. Crosslinking of the electrospun gelatin nanofibers. Polymer., 47: 2911-2917.
39. Weis, S, Emery, J, Becker, K, McBride, D Jr, Omens, J, and, McCulloch, A. 2000. Myocardial mechanics and collagen structure in the osteogenesis imperfecta murine (oim). Circ. Res., 87: 663-669.
40. Coirault, C, Samuel, JL, Chemla, D, Pourny, JC, Lambert, F, Marotte, F, and, LeCarpentier, Y. 1998. Increased compliance in diaphragm muscle of the cardiomyopathic Syrian hamster. J. Appl. Physiol., 85: 1762-1769.
41. Prabhakaran, MP, Kai, D, Ghasemi-Mobarakeh, L, and, Ramakrishna, S. 2011. Electrospun biocomposite nanofibrous patch for cardiac tissue engineering. Biomed. Mater., 6: 055001
42. Kai, D, Prabhakaran, MP, Jin, GR, and, Ramakrishna, S. 2011. Guided orientation of cardiomyocytes on electrospun aligned nanofibers for cardiac tissue engineering. J. Biomed. Mater. Res. Part B-Appl. Biomater., 98B: 379-386.
43. Lee, J, Tae, G, Kim, YH, Park, IS, Kim, S-H, and, Kim, SH. 2008. The effect of gelatin incorporation into electrospun poly(L-lactide-co-epsilon- caprolactone) fibers on mechanical properties and cytocompatibility. Biomaterials., 29: 1872-1879.